Free shipping

Adding Alginate to a PPI: Why the Reflux Trials Differ

A seven-day study favored Gaviscon Advance. A larger Gaviscon Double Action study found a response close to placebo.

Amber medicine bottle with a blank label beside an empty medicine cup, water and blush linen on a cream kitchen table.
In this article
  1. The 2016 study found a short-term advantage
  2. The larger Double Action study did not confirm the response difference
  3. Where an add-on fits in assessment
  4. Check the bottle’s ingredients and cautions

An alginate added to a proton pump inhibitor (PPI) is meant to help symptoms that continue during acid-suppressing treatment. The evidence does not give every liquid sold under the same brand name the same result.

Alginates can form a floating gel barrier, often called a raft, on stomach contents. That offers a different action from suppressing acid production. A trial still has to establish whether the added treatment improves symptoms beyond the improvement with placebo.1

The 2016 study found a short-term advantage

Researchers randomized 136 patients with persistent reflux symptoms despite a once-daily PPI to Gaviscon Advance 10 mL four times daily or placebo for seven days. Both groups continued their PPI.1

Average Heartburn Reflux Dyspepsia Questionnaire reflux scores fell 5.0 points with Advance and 3.5 with placebo; the between-group analysis favored Advance (P = 0.03). Nights with symptoms fell from 3.9 to 2.2 with Advance and 3.6 to 3.0 with placebo, also favoring Advance.1

Seven days can establish a short-term symptom result. It cannot tell us whether an add-on remains useful over months or permits a lasting reduction in prescribed treatment.

The larger Double Action study did not confirm the response difference

A 2017 publication reported two double-blind trials of Gaviscon Double Action added to a standard-dose PPI. The exploratory study included 52 patients. A post hoc analysis, not prespecified, found a response in 75% with Double Action versus 36% with placebo.2

The confirmatory analysis included 262 patients. Response meant at least three fewer “bad” days than during run-in, using a specified questionnaire threshold for heartburn and regurgitation. 51% responded with Double Action and 48% with placebo. The difference was not statistically significant (P = 0.5939).2

The registry records 263 randomized patients, with one placebo recipient excluded from the analysis because it was unknown whether any study medicine had been taken. Participants used 20 mL four times daily for seven days. The manufacturer sponsored the trial.3

The exploratory finding should therefore travel with the larger study’s result. Nor should “51% improved” be read as the benefit caused by the product when nearly as many placebo recipients met the same response definition.

These trials also used different formulations and outcomes. Their numbers do not establish that Advance is superior to Double Action; that would require a direct comparison designed to answer that question.

Where an add-on fits in assessment

The American Gastroenterological Association’s4 2022 expert advice includes alginate antacids as an option for breakthrough symptoms. It says additional treatment should match the patient’s type of GERD, rather than be added automatically. For proven GERD with symptoms during treatment, clinicians may consider pH-impedance monitoring on PPI to investigate the mechanism.4

For an appointment, distinguish burning behind the breastbone, liquid coming back up and repeated belching. Record when each occurs and the medicine taken beforehand. A report of “the reflux medicine isn’t working” gives the clinician less to assess than the symptom, timing and current regimen together.

Check the bottle’s ingredients and cautions

The UK Gaviscon Advance Aniseed liquid currently lists 1,000 mg sodium alginate and 200 mg potassium bicarbonate per 10 mL. Its product information also lists 57.85 mg sodium and 39.06 mg potassium per 5 mL. Those contents matter with sodium restriction, reduced kidney function or a controlled-potassium diet.5

Its instructions say to consider a two-hour interval from other medicines, particularly medicines such as iron, thyroid hormones and certain antibiotics. Ask a pharmacist to check your complete list and the exact product you have. Do not transfer a study’s milliliter amount to a different formulation. The same UK information calls for review if symptoms have not improved after seven days.5

NHS6 guidance advises medical review when heartburn occurs most days, pharmacy treatments do not help, or there is food getting stuck, repeated vomiting or unexplained weight loss. Do not stop prescribed medicine without speaking to a doctor.6

Bloated by Dinner, Chapter 4’s “Time It: Your Belly Clock,” provides a way to record digestive symptoms alongside meal times and medicines, including as-needed remedies. That record can support a visit; it cannot determine which reflux medicine or test you need.

This article compares selected alginate add-on trials and product cautions. Study doses describe research, not a personal treatment schedule. Ask a clinician or pharmacist before changing prescribed reflux treatment.

Read our health disclaimer

Girl Playbook sells this book. It provides education and worksheets, not individualized medical care.

Sources

The research behind this article, in the order it’s cited. How we source our articles.

  1. Reimer and colleagues, Alimentary Pharmacology & Therapeutics, 2016Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor (opens in a new tab)abc
  2. Coyle and colleagues, Alimentary Pharmacology & Therapeutics, 2017Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms (opens in a new tab)ab
  3. EU Clinical Trials Register, 2017Results for EudraCT 2014-003174-17: sodium alginate liquid suspension as add-on therapy (opens in a new tab)↩
  4. American Gastroenterological Association, 2022Personalized approach to the evaluation and management of gastroesophageal reflux disease (GERD) (opens in a new tab)ab
  5. Reckitt Benckiser Healthcare (UK), electronic medicines compendiumGaviscon Advance Aniseed Oral Suspension: Summary of Product Characteristics (opens in a new tab)ab
  6. NHSHeartburn and acid reflux (opens in a new tab)ab

Spotted something out of date? Tell us and we’ll check it.

Private questions deserve good answers.

Ten Playbooks, one for each of the problems women rarely talk about.

Shop the Playbooks